$QGEN (Qiagen NV)

$QGEN {{ '2016-09-12T09:17:25+0000' | timeago}} • Announcement

$QGEN said no meaningful revenue contribution from GeneReader NGS System were included in its 2016 financial forecasts. Company also does not expect a material impact from the court's decision on its full-year 2016 outlook nor anticipates any material changes to its internal 2017 projections. A trial date in the case is scheduled for Nov. 2017.

$A {{ '2018-01-19T17:03:14+0000' | timeago}} • Announcement

$A elected Dow Wilson, CEO of Varian Medical Systems Inc., to its BoD, effective March 20, 2018. Wilson is also a board member of AdvaMed, a U.S. trade association representing 80% of the medical technology firms in the U.S., and Varex Imaging Corp., which was created through the successful spin-off of Varian Medical.

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$GE {{ '2018-01-17T20:56:28+0000' | timeago}} • Announcement

$GE Transportation signed two contracts, valued at over $900MM, with Kazakhstan's state-run railroad Kazakhstan Temir Zholy, as part of its long-term commitment to develop the country's railway infrastructure. The contracts include the delivery of 300 shunter locomotives and an 18-year service agreement.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$AQUA {{ '2018-01-10T13:54:54+0000' | timeago}} • Announcement

$AQUA, which provides water treatment solutions, has appointed Peter Wilver to its board of directors. Wilver, a former senior executive at $TMO, most recently served as Thermo Fisher's EVP and Chief Administrative Officer. Earlier, he held financial management roles at various industrial companies including GE, Honeywell and Grimes Aerospace.

$BSX {{ '2018-01-09T20:36:17+0000' | timeago}} • Announcement

Healthcare solutions firm $BSX said its 4Q17 sales is estimated to have grown about 8% YoY, on a reported basis, to $2.41Bil. In the whole of fiscal 2017, sales advanced 8% annually to $9.05Bil. The growth reflects strong sales performance by all product groups.

$A {{ '2018-01-09T19:50:20+0000' | timeago}} • Announcement

$A acquired Cork, Ireland-based Luxcel Biosciences, a developer of real-time fluorescence plate-reader based in vitro cell assay kits. This acquisition expands $A's cell analysis portfolio with the addition of easy-to-use assay kits that are compatible with industry standard plate-readers.  Financial terms of the deal were not disclosed.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$TMO {{ '2018-01-09T12:43:22+0000' | timeago}} • Announcement

$TMO, a leading medical technology company, has signed an agreement with life sciences firm $ILMN, under which Thermo Fisher will provide Illumina with Ion AmpliSeq technology. The tie-up will help Illumina effectively sell Ion AmpliSeq technology to researchers engaged in scientific studies on its next-generation sequencing (NGS) platforms.

$BAX {{ '2018-01-08T14:03:11+0000' | timeago}} • Announcement

$BAX will acquire two products from Mallinckrodt plc, RECOTHROM Thrombin topical and PREVELEAK Surgical Sealant, for an upfront payment of approx. $153MM and potential contingent payments in future. The deal is expected to be modestly accretive to 2018 adjusted earnings and increasingly accretive thereafter and is expected to close in 1H18.

$ABC {{ '2018-01-03T14:03:33+0000' | timeago}} • Announcement

$ABC completed the acquisition of H. D. Smith, the largest independent wholesaler in the U.S., for $815MM in cash. The acquisition is designed to enhance and expand the company's strategic scale, strengthen its support to community pharmacy and drive long-term, durable value.

$MYGN {{ '2018-01-03T13:32:07+0000' | timeago}} • Announcement

$MYGN said $AZN will use its myChoice HRD Plus test in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza & Avastin. Under the agreement, $MYGN will use its myChoice Plus test to evaluate patients enrolled in an ongoing Phase III trial. Financial terms were not disclosed.

$ACET {{ '2018-01-02T20:11:33+0000' | timeago}} • Announcement

$ACET's finished dosage form generics subsidiary Rising Pharmaceuticals launched the first generic for Efavirenz Capsules. This is an FDA-approved generic version of the reference listed drug, Sustiva from $BMY, which in combination with other drugs is indicated for the treatment of HIV-1 infection in adults and pediatric patients.

$JNJ {{ '2018-01-02T19:20:09+0000' | timeago}} • Announcement

$JNJ declared a cash dividend for 1Q18 of $0.84 per share on the company's common stock. The dividend is payable on March 13, 2018 to shareholders as on Feb 27, 2018.

$BDX {{ '2017-12-29T16:54:30+0000' | timeago}} • Announcement

$BDX acquired $BCR. Beginning with 2Q18, $BDX will report a new Interventional segment structure, which will include a majority of Bard offerings, with the remainder being reported under the Medical segment.

$BDX {{ '2017-12-29T16:54:14+0000' | timeago}} • Announcement

$BDX has acquired $BCR. $BDX does not expect the acquisition to have a material impact on its financial results in 1Q18. $BDX expects the transaction to generate low-single digit accretion to adjusted EPS in FY18, and high-single digit accretion in FY19.

$BDX {{ '2017-12-29T16:53:59+0000' | timeago}} • Announcement

$BDX completed the acquisition of $BCR. Under the terms of the transaction, Bard became a wholly owned subsidiary of $BDX, and each outstanding share of Bard common stock was converted to the right to receive $222.93 in cash without interest, and 0.5077 of a share of $BDX common stock. Bard shares will cease trading and be delisted from the NYSE.

$BDX {{ '2017-12-28T12:35:48+0000' | timeago}} • Announcement

$BDX gets clearance from the Ministry of Commerce of the People's Republic of China (MOFCOM) to acquire $BCR. BD and Bard expect the proposed acquisition to close on Dec. 29. Separately, BD's proposed divestiture of its soft tissue core needle biopsy product line to Merit Medical is conditioned on MOFCOM approval of Merit as the purchaser.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$CNI {{ '2017-12-22T19:58:54+0000' | timeago}} • Announcement

Railroad company $CNI has decided to purchase 200 new locomotives from $GE over the next three years. Production of the locomotives will commence next year at the GE facility in Texas, and the units are expected to be delivered in 2018, 2019 and 2020. The order includes Tier-4 and Tier -3 Evolution Series locomotives.

Recent Transcripts

A (Agilent Technologies Inc.)
Monday, November 20 2017 - 9:30pm
SGMO (Sangamo Biosciences Inc.)
Thursday, November 9 2017 - 10:00pm
ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
RGEN (Repligen Corporation)
Thursday, November 9 2017 - 1:30pm
MYGN (Myriad Genetics, Inc.)
Tuesday, November 7 2017 - 9:30pm
BKD (Brookdale Senior Living Inc.)
Tuesday, November 7 2017 - 2:00pm
QGEN (Qiagen NV)
Tuesday, November 7 2017 - 2:00pm
BIO.B (Bio-Rad Laboratories, Inc.)
Thursday, November 2 2017 - 9:00pm
PDLI (PDL BioPharma, Inc.)
Thursday, November 2 2017 - 8:30pm
GNMK (GenMark Diagnostics, Inc.)
Thursday, November 2 2017 - 8:30pm
ABC (AmerisourceBergen Corporation)
Thursday, November 2 2017 - 12:30pm
BDX (Becton, Dickinson and Company)
Thursday, November 2 2017 - 12:00pm
QDEL (Quidel Corp.)
Wednesday, November 1 2017 - 9:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
TECH (Bio-Techne Corp.)
Tuesday, October 31 2017 - 1:00pm
AET (Aetna Inc.)
Tuesday, October 31 2017 - 12:30pm
ABBV (AbbVie Inc.)
Friday, October 27 2017 - 1:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm
BSX (Boston Scientific Corporation)
Thursday, October 26 2017 - 12:00pm

AlphaGraphics you may like